+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pneumonia Vaccine Market by Vaccine Type, by Product Type and By Sector, by Distribution Channel: Opportunity Analysis and Industry Forecast, 2018-2025

  • ID: 4828550
  • Report
  • 171 pages
  • Allied Analytics LLP
1 of 4
The global pneumonia vaccines market was valued at $7,083 million in 2017 and is expected to reach $10,215 million by 2025, growing at a CAGR of 5% from 2018 to 2025.

Pneumonia is a lung infection that occurs in one or both the lungs caused by bacteria, viruses, or fungi; however, bacterial pneumonia is the most common form occurring in adults.

Pneumonia results in inflammation in the air sacs (known as alveoli) of the lungs, which results in filling the alveoli with fluid (pus cells), thus causing breathing problems. Pneumococcal disease is common in young children, but older adults are at greatest risk of serious pneumococcal infections and even death.

Thus, Center for Disease Control and Prevention (CDC) recommends administration of two pneumococcal vaccines, PCV13 and PPSV23. The key factors that drive the growth of the global pneumonia vaccine market include increase in prevalence of pneumonia across the globe, rise in government focus on immunization programs for pneumonia, and introduction of novel pneumococcal vaccines such as PCV10. However, longer timelines required for pneumonia vaccine production and high cost associated with the development of such vaccines restrain the market growth. Moreover, development of protein-based combination pneumococcal vaccines is expected to provide lucrative opportunities for the expansion of this market.

The global pneumonia vaccine market is segmented based on type, product, distribution channel, sector, and region. Based on type, the market is bifurcated into pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPV). Products covered in the study include Synflorix, Prevnar 13, PPSV- 23, PCV 13-PIPELINE, V114-MERCK, PCV-20-PFIZER, and PCV-10-SII. Based on distribution channel, the market is categorized into distribution partner companies, non-governmental organizations (NGO), and government authorities. Based on sector, the market is bifurcated into public and private. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Analysis by type helps understand the various types of pneumonia vaccines used by healthcare providers.
Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.

Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Vaccine Type
  • Pneumococcal Conjugate Vaccine
  • Pneumococcal Polysaccharide Vaccine
By Product Type
  • Prevnar 13
  • Synflorix
  • Pneumovax 23
By Sector
  • Public
  • Private
By distribution channel
  • Distribution Partner Companies
  • Non-governmental Organizations (NGO)
  • Government Authorities
By Country
  • North America
  • Europe
  • Asia-Pacific
  • LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT (VACCINE PROVIDERS)
  • Glaxosmithkline plc.
  • LG Chem Ltd.
  • Merck & Co., Inc.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Pnuvax Incorporated
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited)
  • SK Bioscience
  • Walvax Biotechnology Co., Ltd.
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2016–2018
3.2.3. Top strategies:
3.3. Porters five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Threat of new entrants
3.3.3. Threat of substitutes
3.3.4. Competitive rivalry
3.3.5. Bargaining power among buyers
3.4. Market share analysis, 2018
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Surge in prevalence of pneumonia across the globe
3.5.1.2. Rise in government focus on immunization programs for pneumonia
3.5.1.3. Increase in focus for novel pneumococcal vaccines
3.5.2. Restraints
3.5.2.1. Longer timelines required for pneumonia vaccine production
3.5.2.2. High cost associated with development of such vaccines
3.5.3. Opportunity
3.5.3.1. Development of protein-based combination pneumococcal vaccines

CHAPTER 4: PNEUMONIA VACCINES MARKET, BY VACCINE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Pneumococcal conjugate vaccine (PCV)
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast
4.3. Pneumococcal polysaccharide vaccine (PPSV/PPV)
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast

CHAPTER 5: PNEUMONIA VACCINES MARKET, BY PRODUCT TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Prevnar 13
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast
5.3. Synflorix
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast
5.4. Pneumovax23
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast
5.5. Pipeline Products

CHAPTER 6: PNEUMONIA VACCINES MARKET, BY SECTOR
6.1. Overview
6.1.1. Market size and forecast
6.2. Public sector
6.2.1. Market size and forecast
6.3. Private sector
6.3.1. Market size and forecast

CHAPTER 7: PNEUMONIA VACCINES MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Distribution partner companies
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast
7.3. Non-governmental Organizations (NGO)
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast
7.4. Government Authorities
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast

CHAPTER 8: GLOBAL PNEUMONIA MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast
8.2. North America
8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast, by type
8.2.4. Market size and forecast, by product type
8.2.5. Market size and forecast, by distribution channel
8.2.6. Market size and forecast, by sector
8.2.7. Market size and forecast, by country
8.2.7.1. The U.S. Pneumonia Vaccine Market
8.2.7.1.1. Market Size and forecast, by type
8.2.7.1.2. Market Size and forecast, by product type
8.2.7.1.3. Market Size and forecast, by distribution channel
8.2.7.1.4. Market Size and forecast, by sector
8.2.7.2. Canada Pneumonia Vaccine Market
8.2.7.2.1. Market Size and forecast, by type
8.2.7.2.2. Market Size and forecast, by product type
8.2.7.2.3. Market Size and forecast, by distribution channel
8.2.7.2.4. Market Size and forecast, by sector
8.2.7.3. Mexico Pneumonia Vaccine Market
8.2.7.3.1. Market Size and forecast, by type
8.2.7.3.2. Market Size and forecast, by product type
8.2.7.3.3. Market Size and forecast, by distribution channel
8.2.7.3.4. Market Size and forecast, by sector
8.3. Europe
8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast, by type
8.3.4. Market size and forecast, by product type
8.3.5. Market size and forecast, by distribution channel
8.3.6. Market size and forecast, by sector
8.3.7. Market size and forecast, by country
8.3.7.1. Germany Pneumonia Vaccine Market
8.3.7.1.1. Market Size and forecast, by type
8.3.7.1.2. Market Size and forecast, by product type
8.3.7.1.3. Market Size and forecast, by distribution channel
8.3.7.1.4. Market Size and forecast, by sector
8.3.7.2. France Pneumonia Vaccine Market
8.3.7.2.1. Market Size and forecast, by type
8.3.7.2.2. Market Size and forecast, by product type
8.3.7.2.3. Market Size and forecast, by distribution channel
8.3.7.2.4. Market Size and forecast, by sector
8.3.7.3. UK Pneumonia Vaccine Market
8.3.7.3.1. Market Size and forecast, by type
8.3.7.3.2. Market Size and forecast, by product type
8.3.7.3.3. Market Size and forecast, by distribution channel
8.3.7.3.4. Market Size and forecast, by sector
8.3.7.4. Spain Pneumonia Vaccine Market
8.3.7.4.1. Market Size and forecast, by type
8.3.7.4.2. Market Size and forecast, by product type
8.3.7.4.3. Market Size and forecast, by distribution channel
8.3.7.4.4. Market Size and forecast, by sector
8.3.7.5. Italy Pneumonia Vaccine Market
8.3.7.5.1. Market Size and forecast, by type
8.3.7.5.2. Market Size and forecast, by product type
8.3.7.5.3. Market Size and forecast, by distribution channel
8.3.7.5.4. Market Size and forecast, by sector
8.3.7.6. Rest of Europe Pneumonia Vaccine Market
8.3.7.6.1. Market Size and forecast, by type
8.3.7.6.2. Market Size and forecast, by product type
8.3.7.6.3. Market Size and forecast, by distribution channel
8.3.7.6.4. Market Size and forecast, by sector
8.4. Asia-Pacific
8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast, by type
8.4.4. Market size and forecast, by product type
8.4.5. Market size and forecast, by distribution channel
8.4.6. Market size and forecast, by sector
8.4.7. Market size and forecast, by country
8.4.7.1. Japan Pneumonia Vaccine Market
8.4.7.1.1. Market Size and forecast, by type
8.4.7.1.2. Market Size and forecast, by product type
8.4.7.1.3. Market Size and forecast, by distribution channel
8.4.7.1.4. Market Size and forecast, by sector
8.4.7.2. China Pneumonia Vaccine Market
8.4.7.2.1. Market Size and forecast, by type
8.4.7.2.2. Market Size and forecast, by product type
8.4.7.2.3. Market Size and forecast, by distribution channel
8.4.7.2.4. Market Size and forecast, by sector
8.4.7.3. India Pneumonia Vaccine Market
8.4.7.3.1. Market Size and forecast, by type
8.4.7.3.2. Market Size and forecast, by product type
8.4.7.3.3. Market Size and forecast, by distribution channel
8.4.7.3.4. Market Size and forecast, by sector
8.4.7.4. Rest of Asia-Pacific Pneumonia Vaccine Market
8.4.7.4.1. Market Size and forecast, by type
8.4.7.4.2. Market Size and forecast, by product type
8.4.7.4.3. Market Size and forecast, by distribution channel
8.4.7.4.4. Market Size and forecast, by sector
8.5. LAMEA
8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast, by type
8.5.4. Market size and forecast, by product type
8.5.5. Market size and forecast, by distribution channel
8.5.6. Market size and forecast, by sector
8.5.7. Market size and forecast, by country
8.5.7.1. Brazil Pneumonia Vaccine Market
8.5.7.1.1. Market Size and forecast, by type
8.5.7.1.2. Market Size and forecast, by product type
8.5.7.1.3. Market Size and forecast, by distribution channel
8.5.7.1.4. Market Size and forecast, by sector
8.5.7.2. South Africa Pneumonia Vaccine Market
8.5.7.2.1. Market Size and forecast, by type
8.5.7.2.2. Market Size and forecast, by product type
8.5.7.2.3. Market Size and forecast, by distribution channel
8.5.7.2.4. Market Size and forecast, by sector
8.5.7.3. Saudi Arabia Pneumonia Vaccine Market
8.5.7.3.1. Market Size and forecast, by type
8.5.7.3.2. Market Size and forecast, by product type
8.5.7.3.3. Market Size and forecast, by distribution channel
8.5.7.3.4. Market Size and forecast, by sector
8.5.7.4. Rest of LAMEA Pneumonia Vaccine Market
8.5.7.4.1. Market Size and forecast, by type
8.5.7.4.2. Market Size and forecast, by product type
8.5.7.4.3. Market Size and forecast, by distribution channel
8.5.7.4.4. Market Size and forecast, by sector

CHAPTER 9: COMPANY PROFILES
9.1. GLAXOSMITHKLINE PLC.
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product Portfolio
9.1.5. Business performance
9.2. LG CHEM LTD.
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
9.2.5. Business performance
9.3. MERCK & CO., INC.
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product Portfolio
9.3.5. Business performance
9.4. PANACEA BIOTEC LIMITED
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance
9.5. PFIZER INC.
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.6. PNUVAX INCORPORATED
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Product portfolio
9.7. SERUM INSTITUTE OF INDIA PVT. LTD.
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Product portfolio
9.8. SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. (BEIJING MINHAI BIOTECHNOLOGY CORPORATION LIMITED)
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Product portfolio
9.9. SK BIOSCIENCE
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Product portfolio
9.10. WALVAX BIOTECHNOLOGY CO., LTD.
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Product Portfolio

*Full List of Tables and Figures Available on Enquiry.

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to this report titled, 'Global Pneumonia Vaccine Market by Vaccine, Product, Sector, and Distribution Channel: Opportunity Analysis and Industry Forecast, 2018 - 2025,' the global pneumonia vaccine market is expected to reach $10,215 million by 2025, registering a CAGR of 5% from 2018 to 2025, in terms of value.

Pneumonia is a lung infection that occurs in one or both the lungs caused by bacteria, virus, or fungi; however, bacterial pneumonia is the most common form occurring in adults.

Pneumonia results in inflammation in the air sacs (known as alveoli) of the lungs, which results in filling the alveoli with fluid (pus cells), thus causing breathing problems. Pneumococcal disease is common in young children, but older adults are at greatest risk of serious pneumococcal infections and even death.

Pneumonia vaccines are primarily administered to children less than 2-years old and adults aged 65 years and older. This vaccine helps individuals provide immunization against 13 types of pneumococcal bacteria that causes infection in the lungs.

The key factors that drive the growth of the global pneumonia vaccine market include increase in prevalence of pneumonia across the globe, rise in government focus on immunization programs for pneumonia, and introduction of novel pneumococcal vaccines such as PCV10. However, longer timelines required for pneumonia vaccine production and high costs associated with development of such vaccines restrain the market growth. Development of protein-based combination pneumococcal vaccines is expected to offer lucrative opportunities for the expansion of this market during the forecast period.

Based on type, pneumococcal conjugate vaccine (PCV) is expected to maintain its dominant (more than half of the market share in 2017) position during the analysis period as it is been widely prescribed as compared to pneumococcal polysaccharide vaccine (PPV).

Based on product, the Prevnar 13 segment held the major market share in 2017 and is expected to dominate the market throughout the forecast period, owing to the wide usage and its efficiency in pneumonia prevention.

Based on distribution channel, the distribution partner companies segment held majority of the market share in 2017, owing to the wide coverage of the private entities. This segment is expected to dominate the market during the forecast period due to majority of private vaccines purchases which are comparatively expensive are distributed from these companies. Hence, the distribution partner companies hold larger share.

Based on sector, the private sector dominates the overall market for pneumonia vaccines and is expected to dominate the market throughout the forecast period due to the higher prices of the vaccine in the private market.

North America accounted for nearly three-fifth of the global market in 2017 and is expected to remain dominant throughout the forecast period. This is attributed to the higher prevalence in the developing countries such as India and China, increase in government healthcare expenditure, rise in demand for better healthcare, and surge in number of childbirths in the region. Moreover, government support and development of protein-based combination pneumococcal vaccines are the factors expected to present new growth opportunities to the players in this market

Key Findings of the Pneumonia Vaccine Market:

The pneumococcal conjugate vaccine (PCV) segment is expected to grow with a CAGR of 5.1% from 2017 to 2025.
Prevnar 13 vaccine is expected to be the fastest growing product with a CAGR of 5.1%.
The distribution partner companies held approximately half of the global market share and is expected to remain dominant throughout the forecast period.
The private segment held more than threeforth share in the global market and is expected to remain dominant throughout the forecast period.
Asia-Pacific is expected to be the fastest growing region, registering a CAGR of 6.6% during the forecast period.

The report provides an extensive competitive analysis and profiles of the key market players such as Glaxosmithkline plc., LG Chem Ltd., Merck & Co., Inc., Panacea Biotec Limited, Pfizer Inc., Pnuvax Incorporated, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited), SK Bioscience, and Walvax Biotechnology Co., Ltd.
Note: Product cover images may vary from those shown
5 of 4

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll